CADE Approves Agreement between Pfizer and AstraZeneca

The Administrative Council for economic Defense (Cade) approved, without restrictions, the deal between the companies Pfizer and AstraZeneca. Both intend to work on the development and commercialization of prescription medicine Nexium, used in treatment of stomach pains, reflux and heartburn. According to a survey done by Cade, the AstraZenena registered 2% in sales volume and 5% of the turnover of the market of drugs in 2014, while Pfizer gained 10% in sales volume and 5% of revenues during the same period.